Monte Rosa Therapeutics (GLUE) said Monday that it has entered into a global development and commercialization license agreement with Novartis (NVS) for VAV1-directed molecular glue degraders, including MRT-6160.
The agreement gives Novartis exclusive global rights to develop, manufacture, and commercialize MRT-6160 and other VAV1 MGDs, Monte Rosa said. Novartis will conduct the clinical studies of MRT-6160, starting with the phase 2 trial, while Monte Rosa is in charge of completing the ongoing phase 1 clinical study, Monte Rosa added.
Monte Rosa said it will receive $150 million upfront from Novartis and will be eligible to receive up to $2.1 billion in development, regulatory, and sales milestones as well as royalties on ex-US net sales.
Monte Rosa added that it will co-fund phase 3 development and share any profits and losses from the manufacturing and commercialization of MRT-6160 in the US.
Monte Rosa's shares jumped more than 39% in recent premarket activity while Novartis shares were down 0.3%.
Price: 6.8100, Change: +1.92, Percent Change: +39.26
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.